Author: Mathilde ROUMIER; Romain PAULE; Matthieu GROH; Alexandre VALLEE; Felix ACKERMANN
Title: Interleukin-6 blockade for severe COVID-19 Document date: 2020_4_22
ID: 0ou5f158_2
Snippet: Notwithstanding the shortcomings of this retrospective small sample-size study, we believe that these preliminary findings support the fostering of research efforts in the fight against COVID-19-induced inflammation, especially before patients require admission to the ICU. there is growing evidence that virally-induced pro-inflammatory cytokines (including Interleukin (IL)1β, IL-6, tumor necrosis factor-α, and granulocyte colony stimulating fac.....
Document: Notwithstanding the shortcomings of this retrospective small sample-size study, we believe that these preliminary findings support the fostering of research efforts in the fight against COVID-19-induced inflammation, especially before patients require admission to the ICU. there is growing evidence that virally-induced pro-inflammatory cytokines (including Interleukin (IL)1β, IL-6, tumor necrosis factor-α, and granulocyte colony stimulating factor) lead to both hyperinflammatory and procoagulatory states at a late-stage of the disease (1, 2) . Such findings are further corroborated by recent studies, which highlighted that high levels of C-reactive protein, IL-6 and D-Dimer upon admission were predictors of mortality (3, 4) . In their recent Comment, Mehta and colleagues exhorted physicians to screen patients with severe COVID-19 for hyperinflammation and suggested that immunosuppressive and/or immunomodulatory drugs should be investigated in this setting (5) . Here, we relate our short-term -yet promising -experience regarding IL6 blockade for severe COVID-19 with tocilizumab.
Search related documents:
Co phrase search for related documents- high level and ICU admission: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35
- high level and ICU admission require: 1
- high level and late disease stage: 1
- high level and necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18
- high level and pro inflammatory cytokine: 1, 2, 3, 4, 5, 6, 7, 8, 9
- high level and recent study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- high level and research effort: 1, 2
- high level and sample size: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33
- high level and sample size study: 1, 2, 3, 4, 5, 6, 7
- high level and small sample size study: 1, 2, 3, 4
- high level and stimulating factor: 1, 2
- high level and tumor necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
- ICU admission and late disease stage: 1
- ICU admission and necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
- ICU admission and patient ICU admission require: 1, 2
- ICU admission and pro inflammatory cytokine: 1
- sample size and small sample size study: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76
- sample size and stimulating factor: 1
- sample size and tumor necrosis factor: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12
Co phrase search for related documents, hyperlinks ordered by date